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BACKGROUND & AIMS: Although hepatitis C virus (HCV)
infection is common in patients with end-stage renal disease,
highly efﬁcacious, well-tolerated, direct-acting antiviral regi-
mens have not been extensively studied in this population.
We investigated the safety and efﬁcacy of ombitasvir co-
formulated with paritaprevir and ritonavir, administered
with dasabuvir (with or without ribavirin) in a prospective
study of patients with stage 4 or 5 chronic kidney disease
(CKD). METHODS: We performed a single-arm, multicenter
study of treatment-naïve adults with HCV genotype 1 infec-
tion, without cirrhosis and with CKD stage 4 (estimated
glomerular ﬁltration rate, 15–30 mL/min/1.73 m2) or stage 5
(estimated glomerular ﬁltration rate, <15 mL/min/1.73 m2 or
requiring hemodialysis). Twenty patients were given ombi-
tasvir co-formulated with paritaprevir and ritonavir, admin-
istered with dasabuvir for 12 weeks. Patients with HCV
genotype 1a infections also received ribavirin (n ¼ 13),
whereas those with genotype 1b infection did not (n ¼ 7). The
primary end point was sustained virologic response (serum
HCV RNA <25 IU/mL) 12 weeks after treatment ended
(SVR12). We collected data on on-treatment adverse events
(AEs), serious AEs, and laboratory abnormalities. RESULTS:
All 20 patients completed 12 weeks of treatment. Eighteen of
the 20 patients achieved SVR12 (90%; 95% conﬁdence in-
terval: 69.9–97.2). One patient death after the end of the
treatment (unrelated to the treatment) and 1 relapse
accounted for the 2 non-SVRs. Adverse events were primarily
mild or moderate, and no patient discontinued treatment due
to an AE. Four patients experienced serious AEs; all were
considered unrelated to treatment. Ribavirin therapy
was interrupted in 9 patients due to anemia; 4 received
erythropoietin. No blood transfusions were performed.
CONCLUSIONS: In a clinical trial, the combination of ombi-
tasvir, paritaprevir, and ritonavir, administered with dasabu-
vir, led to an SVR12 in 90% of patients with HCV genotype 1
infection and stage 4 or 5 CKD. The regimen is well tolerated,
though RBV use may require a reduction or interruption to
manage anemia. ClinicalTrials.gov ID NCT02207088.
Keywords: NS5A Inhibitor; NS3/4A Protease Inhibitor; RUBY-I;
Renal Disease.
Hepatitis C virus (HCV) infection is a global healthproblem with an estimated disease burden
affecting 2.8% of the population.1 In the United States, an
estimated 2.7–3.5 million people have chronic HCV in-
fections, and those who are current or former injection
drug users, human immunodeﬁciency virus–positive, on
hemodialysis, or from highly endemic countries, are
known to be at increased risk.2,3 HCV seroprevalence in
the hemodialysis population has ranged from 7.8% to
44% in the United States and other developed
countries.4–7 In patients with chronic kidney disease
(CKD), the risks for negative outcomes are signiﬁcantly
higher in HCV-infected patients than in those without
infection, including progression to cirrhosis, hepatocellu-
lar carcinoma, liver-related mortality, and progression to
end-stage renal disease (ESRD).4,8–10 While HCV infection
is associated with several glomerulopathies, longstanding
hypertension and type 2 diabetes still account for most
cases of ESRD and mortality in this population.4,11 In
Abbreviations used in this paper: AE, adverse event; CKD, chronic kidney
disease; Ctrough, steady-state trough concentration; DAA, direct-acting
antiviral; DSV, dasabuvir; eGFR, estimated glomerular ﬁltration rate;
ESRD, end-stage renal disease; GT, genotype; IFN, interferon; LLOQ,
lower limit of quantiﬁcation; OBV, ombitasvir; PTV, paritaprevir; r, ritonavir;
RBV, ribavirin; SVR, sustained virologic response; SVR12, sustained viro-
logic response at post-treatment week 12.
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patients who have received a kidney transplant, HCV-
associated liver disease increases the risk for graft rejec-
tion, proteinuria, infection, and diabetes12; therefore,
eradication of HCV infection before transplantation can
improve outcomes in these patients.
Historically, treating HCV infection in patients with
CKD was challenging because of toxicities associated
with the use of interferon (IFN). Reduced renal clearance
of IFN increases the risk and severity of IFN-related
adverse reactions, including ﬂu-like symptoms, depres-
sion, and cytopenias. Low sustained virologic response
(SVR) rates of 33%–37% and discontinuation rates of
17%–30% further limit IFN’s applicability.13,14 The
toxicity of IFN in this population is aggravated by the
concomitant use of renally excreted ribavirin (RBV),
which is minimally eliminated by hemodialysis; thus, the
combination of IFN and RBV is associated with sub-
stantial hematologic toxicity in a population already at
risk for anemia.15 Although RBV can be used with dosage
modiﬁcations in patients with impaired renal func-
tion,16,17 the majority of HCV-infected patients with
ESRD have gone untreated.
Breakthroughs in our understanding of the HCV life-
cycle and the ability to directly interfere with viral
replication within hepatocytes have revolutionized treat-
ment of HCV. The new generation of direct-acting antivi-
rals (DAAs) offers shorter, IFN-free, well-tolerated, highly
efﬁcacious curative therapies. Rates of SVR for these new
DAA combinations approach 95%–100% for HCV geno-
type (GT) 118,19; however, data are limited in patients
with CKD. Ombitasvir (OBV) is an HCV NS5A inhibitor that
is co-formulated with paritaprevir (PTV), an NS3/4A
protease inhibitor and the pharmacokinetic enhancer ri-
tonavir (r), and is coadministered with dasabuvir (DSV), a
non-nucleoside NS5B polymerase inhibitor, for treatment
of GT1 HCV, the most common genotype. This regimen has
shown high rates of SVR at post-treatment week 12
(SVR12) in patients with GT1 infection, synonymous with
viral cure.20 Phase 3 studies of this regimen were con-
ducted in >2000 patients with HCV GT1 infection without
ESRD, with and without compensated cirrhosis, and with
or without prior pegylated IFN/RBV treatment experi-
ence.21–25 When used according to the dosing recom-
mendations in the US label, this regimen achieved SVR in
95.8% of patients with GT1a infection, and 99.7% of pa-
tients with GT1b infection.26,27
As OBV, PTV, DSV, and ritonavir are all hepatically
metabolized with minimal renal clearance, the pharmaco-
kinetics of these DAAs were evaluated in HCV seronegative
persons with mild (creatinine clearance 60–89 mL/min),
moderate (creatinine clearance 30–59 mL/min), and severe
(creatinine clearance 15–29 mL/min) renal impairment.
The plasma exposures observed supports use of this
regimen in HCV-infected patients with renal impairment
with no need for dose adjustments.28 The RUBY-I study
investigated the efﬁcacy and safety of OBV/PTV/r plus DSV
with or without RBV in treatment-naïve HCV GT1-infected
patients with stage 4 or 5 CKD, including those on
hemodialysis.
Methods
Patients and Study Design
Cohort 1 of this study enrolled noncirrhotic adults 18 years
or older with stage 4 or 5 CKD and HCV GT1 infection (HCV
RNA >1000 IU/mL at screening) who had never been treated
for HCV infection. Estimated glomerular ﬁltration rate (eGFR)
was calculated using the Modiﬁcation of Diet in Renal Disease
equation:
eGFR ¼ 175  ðSerum CreatinineÞ1:154  Age0:203
 ð0:742 if femaleÞ  ð1:21 if black raceÞ:
Stage 4 and 5 CKD was deﬁned as an eGFR of 15–30 mL/
min/1.73 m2 and <15 mL/min/1.73 m2, respectively; those on
hemodialysis were considered to have stage 5 CKD or ESRD.
Plasma samples collected at screening were assessed to
determine HCV genotype using the Versant HCV Geno-
type Inno LiPA Assay, version 2.0 or higher (Siemens Health-
care, Berkeley, CA). Exclusion criteria included co-infection
with hepatitis B, human immunodeﬁciency virus, or non-GT1
HCV, patients on peritoneal hemodialysis, history of solid
organ transplant, and laboratory values for albumin <2.8 g/dL,
hemoglobin <10 g/dL, platelet count <25,000  109/L,
total bilirubin 3.0 mg/dL, or an international normalized
ratio >2.3.
Cohort 1 of this study included patients without cirrhosis
only. Patients were considered to be noncirrhotic as deter-
mined by liver biopsy within 24 months before or during
screening (METAVIR score of 3, Ishak score of 4). In the
absence of a biopsy, patients must have had a screening
FibroTest score of 0.72 and an aspartate aminotransferase to
platelet ratio index 2, or a screening transient elastography
(eg, FibroScan) result of <12.5 kPa. Fibrosis stage was
determined according to these tests and additional details
are provided in the Supplementary Material (Supplementary
Table 1).
The study consisted of a 12-week treatment period fol-
lowed by a 24-week post-treatment period. Treatment regi-
mens for patients with HCV GT1a and GT1b infection differed in
accordance with the US prescribing information for OBV/PTV/r
plus DSV.29 Patients with GT1a infection received open-label
OBV/PTV/r (25/150/100 mg once daily) plus DSV (250 mg
twice daily) plus RBV (200 mg once daily) for 12 weeks; GT1b-
infected patients received this regimen without RBV for 12
weeks. Study drug could be administered at any time without
regard for timing of hemodialysis.
All patients signed an informed consent, and the study was
conducted in accordance with the protocol, International Con-
ference on Harmonization guidelines, and ethical principles that
have their origin in the Declaration of Helsinki. All authors had
access to relevant data and reviewed and approved the ﬁnal
manuscript.
Efﬁcacy, Safety, Resistance, and
Pharmacokinetic Assessments
Plasma samples were collected at screening and each study
visit, and were processed by a central laboratory. Efﬁcacy was
assessed by achievement of an SVR12, deﬁned as an HCV RNA
below the level of quantiﬁcation (LLOQ) using the Roche COBAS
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TaqMan real-time reverse transcriptase polymerase chain re-
action assay, version 2.0 (Roche Molecular Systems, Pleasanton,
CA). For this assay, the lower limit of detection for HCV RNA is
15 IU/mL and the LLOQ is 25 IU/mL. The primary end point
was the percentage of patients with SVR12. Secondary end
points included the percentage of patients with on-treatment
virologic breakthrough or post-treatment relapse. Break-
through was deﬁned as an HCV RNA greater than or equal to
the LLOQ after an HCV RNA was lower than LLOQ during
treatment or conﬁrmed increase >1 log10 IU/mL above nadir in
2 consecutive HCV RNA measurements. Relapse was deﬁned as
a conﬁrmed HCV RNA greater than or equal to the LLOQ
between the end of treatment and post-treatment week 12
for those completing treatment with an HCV RNA lower than
the LLOQ.
Adverse events (AEs) occurring from the start of study-drug
administration until 30 days after the last dose were collected
using the MedDRA System Organ Class and preferred term and
were assessed by the investigator for relation to study drug and
severity. Serious AEs were collected from the time of signed
consent until 30 days after the last dose of study drug. Physical
examination with measurement or vital signs and laboratory
assessments were also conducted at each study visit.
A baseline plasma sample was collected before dosing on
day 1 for all patients. Viral RNA isolated from these samples
was analyzed by population sequencing (sensitivity threshold
for variant detection 10%–15%) for variants at signature
resistance-associated positions within the relevant targets, NS3,
NS5A, or NS5B. In patients experiencing virologic failure, the
closest sample in time taken after failure with an HCV RNA
>1000 IU/mL was analyzed by population sequencing for
identiﬁcation of resistance-associated variants.
Pharmacokinetic samples were collected from patients
during each study visit. Patients consenting to intensive phar-
macokinetic sampling had samples drawn at the week 4 study
visit at hour 0 (before study drug administration) and
approximately 2, 4, 5, 6, 8, 12, and 24 hours post-DAA dose.
Plasma concentrations for OBV, PTV, ritonavir, DSV, DSV prin-
cipal metabolite, and RBV were summarized as steady-state
trough levels (Ctrough) based on binning of samples using time
of sample collection after dosing, such that concentrations that
fall in the interval of 10 to 14 hours and 22 to 26 hours after
dosing were considered as Ctrough for twice a day and every day
dosing, respectively.
Ribavirin Management for Decreases
in Hemoglobin
Patients receiving RBV who experienced a decline in serum
hemoglobin >2 g/dL during any 4-week period, or had any
hemoglobin value <10 g/dL, interrupted RBV dosing. If
the hemoglobin level increased above the level that triggered
the interruption, RBV could be resumed at the discretion of the
investigator. Hematologic growth factors or blood transfusions
were permitted at the discretion of the investigator.
Statistical Analyses
All efﬁcacy and safety analyses were performed on the
intent-to-treat population, deﬁned as all patients receiving at
least 1 dose of study drug. A prespeciﬁed modiﬁed intent-to-
treat analysis was conducted, excluding patients who did not
achieve SVR12 for reasons other than virologic failure.
Two-sided 95% conﬁdence intervals were calculated using the
Wilson score method for binomial proportions. SAS, version 9.0,
for the UNIX operating system (SAS Institute, Cary, NC) was
used for all analyses.
Results
Baseline Patient Demographics and
Viral Resistance
Thirty-one patients were screened from September 23,
2014 through February 18, 2015 at 7 sites within the United
States for cohort 1 of this study. Twenty treatment-naïve
patients were enrolled including 13 with HCV GT1a infec-
tion who received OBV/PTV/r þ DSV þ RBV, and 7 with
GT1b infection who received treatment without RBV
(Supplementary Figure 1). The majority of patients were
male, reported black race, and had stage 5 CKD with 14
patients on hemodialysis (Table 1). At baseline, median
creatinine was 6.2 mg/dL, creatinine clearance was 18.1
mL/min, eGFR was 10.9 mL/min/1.73 m2, and hemoglobin
was 12.2 g/dL.
At baseline, variants known to convey resistance to some
inhibitors of HCV NS3, NS5A, and NS5B (non-nucleoside)
were present in the majority of patients. The NS3 variant
Table 1.RUBY-I Baseline Demographics and Disease
Characteristics
Variable
OBV/PTV/r þ
DSV ± RBV (n ¼ 20)
Age, y, median (range) 60 (49–69)
Male, n (%) 17 (85)
Black race, n (%) 14 (70)
Hispanic or Latino ethnicity, n (%) 3 (15)
BMI, kg/m2, median (range) 30.5 (20.3–37.1)
HCV GT1a, n (%) 13 (65)
IL28B non-CC genotype, n (%) 14 (70)
Fibrosis stage, n (%)
F0–F1 10 (50)
F2 6 (30)
F3 4 (20)
HCV RNA, log10 IU/mL, median (range) 6.6 (5.5–7.6)
History of diabetes, n (%) 11 (55)
CKD stage, n (%)
4 (eGFR 15–30 mL/min/1.73 m2) 6 (30)
5 (eGFR <15 mL/min/1.73 m2,
or requiring hemodialysis)
14 (70)
eGFR, mL/min/1.73 m2, median (range) 10.9 (5.4–29.9)
Creatinine, mg/dL, median (range) 6.2 (2.2–10.8)
Creatinine clearance, mL/min,
median (range)
18.1 (8.9–63.1)
Hemoglobin, g/dL, median (range) 12.0 (9.5–16.6)
Total bilirubin, mg/dL, median (range) 0.4 (0.2–0.7)
Albumin, g/dL, median (range) 4.2 (3.0–4.6)
Platelet count, 109/L median (range) 230 (90–432)
INR, median (range) 1.05 (0.90–1.60)
BMI, body mass index; IL28B, interleukin 28B; INR, interna-
tional normalized ratio.
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Q80K/L was detected in 10/13 GT1a-infected patients, and
NS5B S556G was detected in 1 patient. The Q80K variant
confers an approximately 3-fold resistance to PTV, and
S556G variant confers an approximately 30-fold resistance
to DSV. No resistance-associated variants were detected in
NS5A among GT1a-infected patients. In GT1b-infected pa-
tients, NS5A variants L28M, Q54N, or Q62R were each
detected in 1 patient, and Q54H was detected in 3 patients;
no resistance-associated variants were detected in NS3 or
NS5B in GT1b-infected patients. The NS5A variants detected
in GT1b-infected patients are not associated with resistance
to OBV (L28M and Q54H) or have not previously been
selected by OBV therapy (Q54N and Q62R).
Efﬁcacy Outcomes
Plasma HCV RNA was suppressed less than the LLOQ in
15 of 20 (75%) patients by week 2, and in 19 of 20 (95%)
patients by treatment week 4 (Table 2). All 20 patients
completed 12 weeks of treatment and all were virologically
suppressed at the end of treatment. The intent-to-treat
SVR12 rate was 90% (18 of 20; 95% conﬁdence interval:
69.9–97.2). For the 2 patients not achieving SVR12, 1 pa-
tient with HCV GT1a infection died 14 days after completing
treatment of cardiac disease, considered by the investigator
to be unrelated to study drug or RBV. The other patient who
failed to achieve SVR12 had virologic relapse at post-
treatment week 4. This patient, a 49-year-old black male
on hemodialysis, had HCV GT1a infection and F3 ﬁbrosis, an
interleukin 28B CT genotype, and a body mass index of 36.8
kg/m2. Of note, this patient had relatively low reported dose
adherence for OBV/PTV/r (91.8%), and lower adherence for
DSV (91.2%) than most of the other patients. By compari-
son, the mean pill count compliance for OBV/PTV/r was
98.7%, and 96.8% for DSV in the 19 other patients. In
addition, RBV was interrupted on day 58 due to a
hemoglobin decline to 9.8 g/dL (Figure 1F). No signiﬁcant
NS3 or NS5A variants were present at baseline, although
resistance-associated variants D168V in NS3 and Q30R in
NS5A were present at the time of virologic failure. Addi-
tional characteristics for the 2 patients not achieving SVR12
are provided in Supplementary Table 2.
The modiﬁed intent-to-treat SVR12 rate was 95% (18 of
19; 95% conﬁdence interval: 75.4%– 99.1%). Examining
patients with GT1a infection, the intent-to-treat SVR12 was
achieved in 85% (11 of 13) and modiﬁed intent-to-treat
SVR12 rate was 92% (11 of 12). No patients with GT1b
infection failed treatment, thus, the SVR12 rate was 100%
(7 of 7).
Safety Outcomes
Most patients experienced AEs, the majority of which
were mild or moderate in severity (Table 3). No patient
discontinued DAAs due to AE. The most common AEs were
anemia (45%), fatigue (35%), diarrhea (25%), and nausea
(25%). Nine treatment-emergent serious AEs were reported
in 4 patients, although none were attributed to DAAs or RBV.
Serious AEs are summarized in Supplementary Table 2. Post-
baseline grade 3 abnormalities were rare, with 1 patient
having a hemoglobin decline <8 g/dL, described here. No
patients had any signs of hepatic decompensation.
One patient died 14 days after completing 12 weeks of
therapy. This 60-year-old male on hemodialysis with a
history of hypertension was hospitalized on post-
treatment day 2 with hypertensive urgency after report-
ing nausea, emesis, and abdominal and ﬂank pain. Pul-
monary edema was identiﬁed and congestive heart failure
(ejection fraction 15%) was diagnosed on the second day
of hospital admission. On days 11 and 12 of hospitaliza-
tion, the patient experienced lower gastrointestinal
bleeding, became hemodynamically unstable, and expired
due to cardiac arrest. The patient’s hemoglobin level was
stable (9–11 g/dL) during the ﬁnal 6 weeks of treatment,
and was 10 g/dL at the time of hospitalization, suggesting
that RBV-induced anemia likely did not contribute to the
cardiac event. Before his death, this patient’s last post-
treatment laboratory values included an international
normalized ratio of 1.2, albumin of 3.7 g/L, and a total
bilirubin of 0.7 mg/dL.
Anemia and Management of
Hemoglobin Declines
Hemoglobin change (mean ± SD) was 1.38 ± 1.54 g/dL
in patients receiving RBV, and 0.02 ± 0.90 among those
receiving OBV/PTV/r þ DSV alone. Anemia was the most
common AE (n ¼ 9), and was reported only in GT1a-
infected patients receiving DAAs þ RBV. Ribavirin was
interrupted in all 9 of these patients and erythropoietin was
administered to 4 patients, including 2 who had used
erythropoietin before starting treatment; no patient
received a blood transfusion. Interruption of RBV occurred
as early as the ﬁrst week of treatment in 2 patients
(Figure 1A and B), and as late as day 74 (Figure 1C). Three
patients resumed RBV dosing after improvement in
Table 2.On-Treatment and Post-Treatment Virologic
Response, and Reasons for Nonresponse
Response
OBV/PTV/r þ
DSV ± RBV (n ¼ 20)
HCV RNA <25 IU/mL
During treatment
At wk 4 19 (95)
At wk 12 20 (100)
After treatment
At wk 4 18 (90)
At wk 12 18 (90)
Virologic breakthrough during treatment 0
Relapsea 1 (5)
Missing SVR12 1 (5)b
NOTE. Values are n (%).
aVirologic relapse was deﬁned as a conﬁrmed HCV RNA level
of 25 IU/mL between the ﬁnal visit and 12 wk after the last
dose of study drugs among patients who had an HCV RNA
level of <25 IU/mL at the ﬁnal visit.
bPatient died on post-treatment day 14 for reasons unrelated
to study drug.
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hemoglobin levels (Figure 1B, D, and E); the remaining 6
patients completed treatment without the resumption of
RBV. In general, RBV interruption led to improvements in
hemoglobin levels at subsequent on-treatment study visits.
Among the 7 GT1b-infected patients who received OBV/
PTV/r þ DSV without RBV, 2 patients had hemoglobin
measurements <10 g/dL, including one whose baseline
value was <10 g/dL.
One patient experienced a grade 3 hemoglobin value (<8
g/dL), which was related to incorrect RBV dosing during a
hospitalization for a spinal fracture and diskitis (Figure 1E).
Ribavirin dosing had been interrupted during the hospital-
ization beginning on study day 17, but the patient received
extra RBV doses on day 27 (400 mg total) and day 28 (600
mg total). Ribavirin was then interrupted again, and eryth-
ropoietin was administered beginning on day 28. The pa-
tient’s hemoglobin level declined to 7.7 g/dL on day 32 and
to a nadir value of 7.0 g/dL on day 35, but subsequently
improved and was >10 g/dL by the end of treatment. The
patient achieved SVR12.
Figure 1. Hemoglobin
levels for patients inter-
rupting RBV. Nine pa-
tients interrupted RBV due
to hemoglobin declines.
Plotted are individual
patient hemoglobin levels
over time for 6 patients;
plots for the remaining 3
patients are located in
Supplementary Figure 2.
Ribavirin was resumed in 3
patients (B, D, and E).
Blue-ﬁlled symbols indi-
cate RBV administration.
Black-ﬁlled symbols indi-
cate when RBV was inter-
rupted. Red-ﬁlled symbols
indicate administration of
erythropoietin. Open sym-
bols indicate hemoglobin
levels during the post-
treatment period. The
horizontal dotted line
demarcates 10 g/dL. BL,
baseline; EOT, end of
treatment; PTW, post-
treatment week.
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Pharmacokinetic Results
The binned geometric mean trough plasma concentra-
tions of PTV, ritonavir, OBV, and DSV in patients with stages
4 and 5 CKD were generally comparable with the values in
HCV GT1-infected patients without ESRD enrolled in phase
3 studies of these DAAs (Figure 2). The Ctrough geometric
means for DSV principal metabolite and RBV were approx-
imately 15%–38% lower and 27%–36% lower, respectively,
compared with the range of values observed in phase 3
studies in patients without ESRD. Intensive pharmacokinetic
data were available from 3 patients: 1 with stage 4 CKD, 1
with stage 5 ESRD obtained on a nonhemodialysis day, and
1 with stage 5 ESRD obtained on a hemodialysis day. Due to
the limited sample size, these data are not summarized here.
For the stage 5 CKD patient with pharmacokinetic data
collected during hemodialysis, the arterial and venous
concentrations of all DAAs were comparable (<17%
change) before the start of hemodialysis, 1 hour after the
start of hemodialysis, and at the end of hemodialysis.
Although these data are limited, they suggest that hemodi-
alysis does not extract these DAAs or ritonavir from the
bloodstream.
Discussion
Before the era of IFN-free treatment regimens, few HCV-
infected patients with ESRD underwent HCV treatment due
to the toxicity and poor tolerability of the available regi-
mens. As such, these patients have not beneﬁtted from HCV
cure and have remained at risk for liver disease progression,
including complications of cirrhosis, hepatocellular carci-
noma, and death. New treatment paradigms have emerged
with the use of DAAs, with new opportunities for cure in this
difﬁcult-to-treat population. In this study, 20 patients with
HCV GT 1 infection and severe CKD or ESRD, including those
Table 3.Treatment-Emergent Adverse Events and Laboratory Abnormalities
Variable
GT1a
OBV/PTV/r þ DSV þ RBV (n ¼ 13)
GT1b
OBV/PTV/r þ DSV (n ¼ 7)
Any AE 13 (100) 6 (86)
Any AE assessed as being related to DAAs 8 (62) 2 (29)
Serious AE 3 (23) 1 (14)
AE leading to study drug discontinuation 0 0
Death 1 (8) 0
AEs occurring in 15% of patients
Anemia 9 (69) 0
Fatigue 5 (38) 2 (29)
Diarrhea 4 (31) 1 (14)
Nausea 5 (38) 0
Headache 3 (23) 0
Peripheral edema 1 (8) 2 (29)
Hemoglobin
Grade 2 (<10–8 g/dL) 7 (54) 2 (29)
Grade 3 (<8–6.5 g/dL) 1 (8) 0
Total bilirubin
Grade 2 (>1.5–3  ULN) 2 (15) 0
Grade 3 (>3–20  ULN) 0 0
Alanine aminotransferase
Grade 3 (>5–20  ULN) 0 0
Aspartate aminotransferase
Grade 3 (>5–20  ULN) 0 0
NOTE. Values are n (%).
ULN, upper limit of normal.
Figure 2.Mean plasma trough concentrations for study
drugs. Individual patients’ plasma drug trough concentrations
are plotted using a binned time interval of >22–26 hours for
PTV, RTV, and OBV, and an interval of >10–14 hours for DSV,
DSV M1, and RBV. Horizontal lines and the table indicate the
geometric mean in ng/mL; whiskers indicate 95% conﬁdence
intervals. DSV M1, dasabuvir principal metabolite; CV, coef-
ﬁcient of variation.
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on hemodialysis, received 12 weeks of OBV/PTV/r þ DSV
with or without RBV. The SVR12 rate was 90% with 1
patient relapsing after treatment and 1 patient death during
the post-treatment period due to a serious AE unrelated to
study drug. Inadequate study drug adherence might have
played a role in the virologic failure. No patients with
baseline resistance-associated variants experienced viro-
logic failure.
No patients in this study discontinued treatment and the
reported side effects were largely similar to those seen in
patients with normal renal function. The exception was
anemia, which occurred in a substantially higher proportion
of patients than was seen in the phase 3 studies of this
regimen. However, hemoglobin declines are not unexpected
because patients with ESRD have pre-existing anemia due to
insufﬁcient erythropoietin production and have limited
ability to excrete RBV, leading to hemolysis. Due to the
known impact of ESRD on RBV excretion, the dose of RBV
was reduced to 200 mg/d, with provisions to discontinue
RBV if hemoglobin levels met prespeciﬁed thresholds.
Despite the reduced starting dose of RBV in this study, 9 of
the 13 patients who received RBV met these thresholds and
discontinued RBV. Most hemoglobin declines occurred in
the ﬁrst month of treatment. In addition to RBV interrup-
tion, erythropoietin was used in 4 of these patients,
although no patient received blood transfusion.
Hematologic toxicity is of particular importance in this
patient population characterized by a high prevalence of
cardiovascular comorbidities.11,30,31 One death occurred in
this cohort, in a 60-year-old man with hypertensive
nephropathy on hemodialysis who experienced hyperten-
sive urgency and cardiomyopathy shortly after completing
his 12-week course of treatment. Although the events
leading to this patient’s death were not related to the use of
RBV or DAAs, this case and others reported with other DAA
regimens highlight the fragile nature of these patients and
the need for careful selection of patients who would beneﬁt
from HCV treatment, as well as the need for close moni-
toring during treatment.32 Close collaboration between
HCV-treating clinicians and a nephrologist may be needed to
ensure that HCV treatment can be delivered safely and
effectively.
Treatment of HCV in patients with severe renal disease
should rely on DAAs that are not predominantly renally
cleared to avoid accumulation of drug and/or metabolites.
Unlike most DAAs, the metabolite of the nucleotide
analogue NS5B polymerase inhibitor sofosbuvir is primarily
cleared by the kidney, resulting in exposures 1280% higher
when dosed 1 hour before hemodialysis and 2070% higher
when dosed 1 hour after hemodialysis in patients with
ESRD.33 As a result, no dosage recommendation is given for
sofosbuvir in patients with eGFR <30 mL/min/1.73
m2.33,34 Although most other DAAs are metabolized by the
liver, increased drug exposures have been reported with
simeprevir and daclatasvir in patients with severe renal
impairment.35,36
Ombitasvir, paritaprevir, ritonavir, and dasabuvir are all
metabolized by the liver, and phase 1 studies demonstrated
that no dose adjustments are needed in patients with mild,
moderate, or severe renal impairment.28 Drug exposures of
the DAAs in this study were within the range of levels
observed in 1278 patients without stage 4 or 5 CKD
included in phase 3 studies of this regimen. Additionally,
intensive pharmacokinetic analyses of the 3 DAAs and ri-
tonavir in a limited number of patients suggest that he-
modialysis does not extract any of these drugs from the
blood and is not a signiﬁcant clearance pathway for this
regimen. Study drugs could be administered without regard
to the timing of hemodialysis. With an RBV dose roughly
one-ﬁfth the normal starting dose, RBV levels were 27%–
36% lower than those observed in patients with normal
renal function.
Clinical studies evaluating the efﬁcacy of DAA-based HCV
regimens are sparse in patientswith severe CKDor ESRD. The
investigational regimen of elbasvir and grazoprevir achieved
SVR12 in 115 of 122 (94.3%) GT1-infected patients with
stage 4 or 5 CKD, including patients on hemodialysis with
prior treatment experience and with cirrhosis, and was well
tolerated.32 Conclusions in patients with cirrhosis (n ¼ 6)
may require further study. There are fewer data available on
the use of other DAA regimens in this population.
Limitations of cohort 1 of this study include the small
sample size and exclusion of patients with prior HCV
treatment failure or with cirrhosis, both of which have his-
torically had poorer response to therapy with IFN-based
regimens and some DAA regimens. Treatment-experienced
patients were excluded in cohort 1 of this study because
the majority of HCV-infected adults with severe renal
disease were likely to be treatment-naïve due to the poor
tolerability of pegylated IFN/RBV in patients with renal
insufﬁciency. In addition, the mean hemoglobin level at
study outset was 12 g/dL, which makes these patients
better able to tolerate RBV-induced decreases in hemoglo-
bin compared with patients with more signiﬁcant baseline
anemia. Therefore, this study does not provide guidance for
CKD patients with much lower baseline hemoglobin levels,
who might not tolerate even a small decrease. Alternative
RBV dosing schedules and RBV-free arms for patients with
HCV GT1a were not assessed in cohort 1 of this study.
Continued study of this regimen is warranted to determine
whether the safety ﬁndings in this study are generalizable to
a larger number of patients.
The results of this study are important for hepatologists,
gastroenterologists, and infectious disease specialists who
are accustomed to treating HCV-infected patients with DAA
therapy but who may not yet have seen sufﬁcient data to
initiate DAA therapy in patients with ESRD. Nephrologists,
who may not be accustomed to treating HCV, should also be
aware that treatment options may now be available that can
help prevent the end-stage sequelae of HCV. How treatment
of HCV infection affects early or intermediate stages of CKD
and how achievement of SVR impacts strategies for kidney
transplantation in patients with ESRD require more study.
In conclusion, this study demonstrated that OBV/PTV/
r þ DSV ± RBV for 12 weeks was efﬁcacious in a pre-
liminary cohort of patients with HCV GT1 infection and
stage 4 or 5 CKD, including those on hemodialysis. Treat-
ment was well tolerated, as evidenced by high adherence to
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medication and ability to complete the study without
discontinuation due to AE. Hemoglobin declines were
frequent and managed with interruption of RBV and
administration of erythropoietin as needed, but did not
appear to affect efﬁcacy. Cohort 2 of this study will inves-
tigate additional GT1-infected patients, including pegylated
IFN/RBV treatment-experienced patients and those with
compensated cirrhosis.
Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2016.02.078.
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